Metraipolis › archive › dc_56e8d60607bc

Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities — Europe PMC PMID:42558429

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42558429
DOI
10.3389/fonc.2026.1921345
License (as archived)
solo-consultazione
Archived
2026-10-17T23:55:27.283Z
SHA-256 of the archived text
92c857097dbbd3fb75acdacb696f7596965f6cd17904a9d3128fe55a6c20ed07
Stable URL of this page
https://metraipolis.com/documento/dc_56e8d60607bc

How to cite

Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities — Europe PMC PMID:42558429 — Europe PMC (en), https://europepmc.org/article/MED/42558429 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_56e8d60607bc (Metraipolis archive dc_56e8d60607bc, sha256 92c857097dbbd3fb75acdacb696f7596965f6cd17904a9d3128fe55a6c20ed07)
BibTeX
@misc{dc56e8d60607bc,
  title = {Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities — Europe PMC PMID:42558429},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42558429},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_56e8d60607bc; sha256 92c857097dbbd3fb75acdacb696f7596965f6cd17904a9d3128fe55a6c20ed07},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42558429. Agents can read the archived copy with the MCP tool read_document.